LAVAL, QC, Feb. 9 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that it will host a conference call on Thursday, February 16, 2006 at 8:30 a.m. (ET) to discuss its fourth quarter 2005 financial results. Labopharm will report its fourth quarter 2005 financial results via news release at approximately 7:00 a.m. the same day.
To access the conference call by telephone, dial 416-644-3428 or 1-800-814-4941. Please connect approximately fifteen minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Thursday, February 23, 2006 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21173669 followed by the number sign.
A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.
About Labopharm Inc.
Labopharm Inc. is an international, specialty pharmaceutical company focused on the development of drugs incorporating Contramid(R), the Company’s proprietary advanced controlled-release technology. Labopharm’s lead in-house product, a once-daily formulation of the analgesic tramadol, is marketed in Germany and has received regulatory approval in 21 other European countries. In the U.S., the Company secured a licensing and distribution agreement with Purdue Pharma L.P., the premier marketer of long-acting pain medications in that country. The Company’s pipeline includes a combination of in-house and partnered programs with products both in clinical trials and in preclinical development. For more information, please visit www.labopharm.com
This press release contains forward-looking statements, which reflect the Corporation’s current expectations regarding future events. The forward- looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the successful and timely completion of clinical studies, the uncertainties related to the regulatory process and the commercialization of the drug thereafter. Investors should consult the Corporation’s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Corporation disclaims any obligation to update these forward-looking statements.
Labopharm Inc.
CONTACT: At Labopharm, Warren Whitehead, Chief Financial Officer, Tel:(450) 680-2423; At The Equicom Group, Jason Hogan, Investor Relations, Tel:(416) 815-0700, jhogan@equicomgroup.com; At Feinstein Kean Healthcare,Harriet Ullman, U.S. Media Relations, Tel: (617) 577-8110,hullman@fkhealth.com
